PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair
背景（Background）
PCSK9 is a crucial protein in the regulation of plasma cholesterol homeostasis. It binds low density lipoprotein receptor (LDL R) to enhance the degradation of LDL R. Therefore, inhibition of PCSK9 has been considered a promising strategy to prevent the receptor from being degraded and promote removal of LDL cholesterol from circulation.
原理（Assay Principles）
This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new PCSK9 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human LDL R and in-house developed biotinylated PCSK9 protein. This product is uniquely suitable for rapid high-throughput screening of putative PCSK9 inhibitors. Briefly, we provide you with a biotinylated human PCSK9 protein, a human LDL R protein, an anti-PCSK9 neutralizing antibody (as method verified Reference), and Streptavidin-HRP reagent.
Your experiment will include 4 simple steps:
1. Coat the plate with human LDL R.
2. Add your molecule of interest to the plates.
3. Add human PCSK9-Biotin to the plates.
4. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
5. Finally, the ability of your compound to inhibit PCSK9: LDL R binding will be determined by comparing OD readings among different experimental groups.
应用说明（Application）
This pair is useful for screening for inhibitors of human PCSK9 binding to human LDL R.
It is for research use only.
重构方法（Reconstitution）
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
存储（Storage）
Upon receipt, please store all items at -70°C.
After reconstitution, the stock solution should be kept at -70°C.
关键字： PCSK9 ELISA Kit;PCSK9试剂盒;PCSK9 ELISA试剂盒;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。